LIVE WEBINAR: Wednesday, April 28, 2021, 12:00 PM – 1:00 PM Eastern Time

Dissecting the Decision: Investigator Perspectives on Key Issues in the Management of Common Cancers

13th Annual Oncology Grand Rounds NCPD Webinar Series

Urothelial Bladder Carcinoma

Register for the REPLAY of this event taking place on May 17

Register for this complimentary event with the “Register ” button above,
which will take you to our Zoom registration page.

Elisabeth I Heath, MD
Associate Center Director, Translational Sciences
Chair, Genitourinary Oncology Multidisciplinary Team
Professor of Oncology and Medicine
Hartmann Endowed Chair for Prostate Cancer Research
Director, Prostate Cancer Research
Karmanos Cancer Institute
Wayne State University School of Medicine
Detroit, Michigan

Daniel P Petrylak, MD
Professor of Internal Medicine (Medical Oncology) and Urology
Yale School of Medicine
New Haven, Connecticut

Nurse Case Presentations By
Monica Averia, MSN, AOCNP, NP-C
Oncology Nurse Practitioner
USC Norris Cancer Center
Los Angeles, California

Kathy D Burns, RN, MSN, AGACNP-BC, OCN
GU Medical Oncology
City of Hope Comprehensive Cancer Center
Duarte, California

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by an educational grant from Astellas and Seagen Inc.

Wednesday, April 28, 2021
12:00 PM – 1:00 PM Eastern Time
Live NCPD-accredited webinar

Topics to Be Discussed

  • Overview of urothelial bladder cancer (UBC) incidence and prognosis, patient signs and symptoms at presentation and diagnostic/staging considerations; key patient- and disease-specific factors affecting disease management
  • Management of non-muscle-invasive bladder cancer, including the efficacy and side effects of bacillus Calmette-Guerin (BCG) intravesical immunotherapy and treatment options for patients unresponsive to BCG
  • Systemic treatments for newly diagnosed metastatic UBC: Mechanism of action, efficacy and immune-related side effects of recently approved immune checkpoint inhibitors (ICIs); roles of PD-L1 status and eligibility for platinum-containing chemotherapy in patient selection for ICI treatment
  • Balancing benefit and side effects in the selection and sequencing of therapies for patients with metastatic UBC who have experienced relapse after chemotherapy and ICIs
  • Role of molecular testing to identify actionable therapeutic targets (eg, FGFR mutation); efficacy and side effects of available agents (eg, erdafitinib)
  • Newly approved agents: Mechanism of action, efficacy, and incidence, type and management of associated adverse events

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of bladder cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Identify available clinical trial data supporting the use of immune checkpoint inhibitors for the treatment of urothelial bladder carcinoma (UBC) to determine the current utility of these agents in clinical practice.
  • Consider the recent FDA approval of pembrolizumab for patients with BCG-unresponsive, high-risk non-muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy, and effectively identify those appropriate for this novel treatment approach.
  • Evaluate available and emerging data and ongoing research investigating anti-PD-1/PD-L1 antibodies as neoadjuvant or adjuvant therapy for muscle-invasive bladder cancer, and discern the current and potential role of these strategies.
  • Review available clinical trial data evaluating anti-PD-1/PD-L1 antibodies as maintenance therapy after first-line chemotherapy for patients with previously untreated metastatic UBC, and consider the role of this approach in routine practice.
  • Appraise available research data and ongoing clinical trials evaluating novel treatment approaches with anti-PD-1/PD-L1 antibodies, and counsel appropriately selected patients about participation in active protocols.
  • Describe the frequency of fibroblast growth factor receptor (FGFR) abnormalities in patients with metastatic UBC, and recognize the FDA approval of erdafitinib for individuals with advanced UBC and susceptible FGFR3 or FGFR2 genetic alterations whose disease has progressed during or after at least 1 line of platinum-containing chemotherapy.
  • Develop an understanding of the mechanism of action of and pivotal clinical trial findings with enfortumab vedotin for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with this novel compound would be appropriate.
  • Educate patients about the side effects associated with approved therapies commonly employed in the management of UBC, and provide preventive strategies to reduce or ameliorate these toxicities.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with UBC in order to optimize clinical and quality-of-life outcomes.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NCPD Designation Statements
This educational activity for 1 contact hour is provided by RTP.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr HeathAdvisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Sanofi Genzyme; Consulting Agreement: Astellas; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Caris Life Sciences, Celgene Corporation, Celldex Therapeutics, Corcept Therapeutics, CureMeta LLC, Dendreon Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, Esanik Therapeutics, Fortis Therapeutics, Genentech, a member of the Roche Group, GlaxoSmithKline, Ignyta Inc, Inovio Pharmaceuticals Inc, Medivation Inc, a Pfizer Company, Merck, Merck Sharp & Dohme Corp, Oncolys BioPharma, Plexxikon Inc, Seagen Inc, Synta Pharmaceuticals Corp, Takeda Oncology, Tokai Pharmaceuticals Inc, Zenith Epigenetics; Paid Travel: Astellas, Caris Life Sciences, Seagen Inc; Speakers Bureau: Sanofi Genzyme. Dr PetrylakConsulting Agreements: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bicycle Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Exelixis Inc, Incyte Corporation, Janssen Biotech Inc, Lilly, Mirati Therapeutics, Monopteros Therapeutics, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seagen Inc, UroGen Pharma; Contracted Research: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics Inc, Bristol-Myers Squibb Company, Clovis Oncology, Eisai Inc, Endocyte Inc, Genentech, a member of the Roche Group, Innocrin Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Mirati Therapeutics, Novartis, Pfizer Inc, Progenics Pharmaceuticals Inc, Replimune, Roche Laboratories Inc, Sanofi Genzyme, Seagen Inc; Ownership Interest: Bellicum Pharmaceuticals Inc (sold 7/2020), Tyme Inc (sold 10/2019).

CONTRIBUTING NURSESMs Averia had no relevant conflicts of interest to disclose. The following nurse practitioner reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Ms BurnsAdvisory Committee: EMD Serono Inc; Speakers Bureau: Astellas, Exelixis Inc, Merck, Pfizer Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.

RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by an educational grant from Astellas and Seagen Inc.